<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02547688</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00046727</org_study_id>
    <nct_id>NCT02547688</nct_id>
  </id_info>
  <brief_title>Assessment of the Tolerability of Dry Airflow in the Nasal Cavity During Sleep</brief_title>
  <official_title>Assessment of the Tolerability of Dry Airflow in the Nasal Cavity During Sleep</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Preliminary data show that high flow nasal air has been shown to reduce promote heat exchange&#xD;
      due to evaporation of nasal mucus by the air flow resulting in heat loss. It is unclear&#xD;
      whether unidirectional nasal airflow is well tolerated in healthy individuals. The central&#xD;
      hypothesis of this proposal is that dry high flow nasal air will be sufficiently tolerated in&#xD;
      healthy adults.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Study sponsor discontinued&#xD;
  </why_stopped>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">January 2018</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Subjective Tolerability using Questionnaire</measure>
    <time_frame>Baseline</time_frame>
    <description>Participant response to nasal high flow using 7 point Likert scale</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Healthy Adults</condition>
  <arm_group>
    <arm_group_label>Nasal High Flow</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All subjects are in this group</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Nasal High Flow</intervention_name>
    <arm_group_label>Nasal High Flow</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy men and women&#xD;
&#xD;
          -  Able to consent&#xD;
&#xD;
          -  Age â‰¥ 18&#xD;
&#xD;
          -  BMI&lt;30kg/m2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous diagnosis of obstructive sleep apnea or sleep disorder&#xD;
&#xD;
          -  History of Constant Positive Airway Pressure treatment for Obstructive Sleep Apnea&#xD;
&#xD;
          -  History of recurrent epistasis&#xD;
&#xD;
          -  Pregnancy (self-report)&#xD;
&#xD;
          -  Deviated nasal septum&#xD;
&#xD;
          -  Unstable cardiovascular disease (decompensated Congestive Heart Failure, myocardial&#xD;
             infarction or revascularization procedures, unstable arrhythmias)&#xD;
&#xD;
          -  Uncontrolled hypertension with BP &gt; 190/110&#xD;
&#xD;
          -  Daytime hypoxemia with oxygen saturation&lt;90% (measured at history and physical&#xD;
             examination)&#xD;
&#xD;
          -  Supplemental oxygen use&#xD;
&#xD;
          -  Work in transportation industry as a driver or pilot.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jason Kirkness, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <study_first_submitted>September 9, 2015</study_first_submitted>
  <study_first_submitted_qc>September 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 11, 2015</study_first_posted>
  <last_update_submitted>August 7, 2017</last_update_submitted>
  <last_update_submitted_qc>August 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

